Page last updated: 2024-11-05

thalidomide and ENT Diseases

thalidomide has been researched along with ENT Diseases in 2 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Paulus, WE1
Lindemann, J1
Friebe-Hoffmann, U1
Jörgensen, G1

Reviews

1 review available for thalidomide and ENT Diseases

ArticleYear
[Human genetic aspects of inborn ear, nose, and throat diseases].
    HNO, 1985, Volume: 33, Issue:6

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Acrocephalosyndactylia; Child, Preschool; Chro

1985

Other Studies

1 other study available for thalidomide and ENT Diseases

ArticleYear
[Otorhinolaryngological diseases in pregnancy-which drugs are approved?]
    HNO, 2022, Volume: 70, Issue:3

    Topics: Child; Female; Humans; Otorhinolaryngologic Diseases; Pharmaceutical Preparations; Pregnancy; Thalid

2022